Analysts See $-0.23 EPS for AzurRx BioPharma, Inc. (AZRX)

February 11, 2018 - By Migdalia James

 Analysts See $ 0.23 EPS for AzurRx BioPharma, Inc. (AZRX)

Analysts expect AzurRx BioPharma, Inc. (NASDAQ:AZRX) to report $-0.23 EPS on February, 12.After having $-0.28 EPS previously, AzurRx BioPharma, Inc.’s analysts see -17.86 % EPS growth. The stock increased 1.63% or $0.0499 during the last trading session, reaching $3.1099. About 58,239 shares traded or 8.34% up from the average. AzurRx BioPharma, Inc. (NASDAQ:AZRX) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $35.93 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

More notable recent AzurRx BioPharma, Inc. (NASDAQ:AZRX) news were published by: Globenewswire.com which released: “AzurRx BioPharma Announces Publication of US Patent Application for AZX1101” on December 20, 2017, also Globenewswire.com with their article: “AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants” published on January 17, 2018, Reuters.com published: “BRIEF-Azurrx Biopharma enters into sublicense agreement with Transchem” on August 12, 2017. More interesting news about AzurRx BioPharma, Inc. (NASDAQ:AZRX) were released by: Globenewswire.com and their article: “AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)” published on December 04, 2017 as well as Globenewswire.com‘s news article titled: “AzurRx BioPharma Announces Closing of $5.0 Million Private Financing” with publication date: June 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.